CIK: 885725
Company Name: BOSTON SCIENTIFIC CORP
Form Type : 10-K
Filing Date: 2019-02-19
Accession Number: 0000885725-19-000011


Item 1 Business As part of our strategic imperatives to drive global expansion, described in Emerging Markets 38 was primarily driven by strong performance in each region, particularly in Asia Pacific and U.S., and growth in our interventional oncology product solutions, drug eluting technologies, including Ranger Drug Coated Balloon and Eluvia Drug Eluting Vascular Stent System and core technologies to treat vascular diseases. increase . This year over year 2017 basis points from foreign currency fluctuations, as compared to 60 impact of positive and the 9.2 percent included operational net sales growth of increase . This 2017 , as compared to 2018 , in 9.8 percent , or $106 million d increase . Our Peripheral Interventions net sales 2018 of our consolidated net sales in 12 percent represented approximately $1187 billion Our net sales of Peripheral Interventions products of Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial diseases, including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular diseases, as well as products to diagnose, treat and ease various forms of cancer. Peripheral Interventions was primarily related to our structural heart therapies, including sales of our WATCHMAN Left Atrial Appendage Closure (LAAC) Device, our ACURATE Transcatheter Aortic Valve Replacement (TAVR) platform purchased as part of our Symetis acquisition, our Sentinel Cerebral Embolic Protection System purchased as part of our Claret acquisition and our complex percutaneous coronary interventions (PCI) product offerings, partially offset by a decline in sales of our drug eluting coronary stent product offerings. increase . This year over year 2017 basis points from foreign currency fluctuations, as compared to 50 impact of positive and the 6.6 percent included operational net sales growth of increase This . 2017 , as compared to 2018 , in 7.1 percent , or $171 million d increase . Our Interventional Cardiology net sales 2018 of our consolidated net sales in 26 percent represented approximately $2590 billion Our net sales of Interventional Cardiology products of Our Interventional Cardiology business develops and manufactures technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. Interventional Cardiology Cardiovascular was primarily driven by the successful launch of Spectra WaveWriter Spinal Cord Stimulator (SCS) Systems in the U.S. and the continued strong sales growth in our Vercise Deep Brain Stimulation (DBS) Systems. increase . This year over year 2017 basis points from foreign currency fluctuations, as compared to 20 impact of positive and the 225 percent included operational net sales growth of increase . This 2017 , as compared to 2018 , in 227 percent , or $144 million d increase Neuromodulation net sales . 2018 of our consolidated net sales in eight percent represented $779 million Our net sales of Neuromodulation products of Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Neuromodulation was primarily driven by global expansion of our Rhythmia Mapping System products and capital equipment offerings, our expanded portfolio of navigation enabled open irrigated catheters, including the Blazer IntellaNav MiFi Open Irrigated catheter, and advanced diagnostic catheters, including the IntellaMap Orion Mapping Catheter. increase . This year over year 2017 basis points from foreign currency fluctuations, as compared to 120 impact of positive and the 10.9 percent included operational net sales growth of increase . This 2017 , as compared to 2018 , in 121 percent , or $33 million d increase . Our Electrophysiology net sales 2018 of our consolidated net sales in 3 percent represented approximately $311 million f Our net sales of Electrophysiology products o . Our Electrophysiology business develops and manufactures less invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart Electrophysiology 37 was driven by the global strength of our implantable cardioverter defibrillator (ICD), our implantable cardiac resynchronization therapy defibrillator (CRT D) and our subcutaneous implantable cardiac defibrillator (S ICD) products. Our current generation of ICD and CRT D products were both favorably impacted by our U.S. magnetic resonance imaging (MRI) safe conditional labeling, which was approved by the FDA in September 2017 and launched in the fourth quarter of 2017. Our defibrillator growth was also driven by a combination of the ongoing global commercialization of our RESONATE family of ICD and CRT D devices which includes our HeartLogic Heart Failure (HF) Diagnostic and the increasing market penetration of our S ICDs. This year over year defibrillator growth was partially offset by declines in our pacemaker portfolio due to market share loss as a result of competitive product entrance. increase This year over year . 2017 basis points from foreign currency fluctuations, as compared to 80 impact of positive and the 21 percent included operational net sales growth of increase . This 2017 o , as compared t 2018 , in 29 percent , or $56 million d increase . Our net sales of CRM products 2018 of our consolidated net sales in 20 percent represented approximately $1951 billion Our net sales of CRM products of Our Cardiac Rhythm Management (CRM) business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Cardiac Rhythm Management Rhythm and Neuro was primarily attributable to growth in sales of our st1 franchise, including our LithoVue Digital Flexible Ureteroscope, our men's health products and our benign prostatic hyperplasia (BPH) product family, including the Rez m System purchased as part of our NxThera acquisition and the SpaceOAR Hydrogel System purchased as part of our Augmenix acquisition. increase This year over year . 2017 basis points from foreign currency fluctuations, as compared to 20 impact of positive and the 10.6 percent included operational net sales growth of increase This . 2017 , as compared to 2018 , in 10.8 percent , or $122 million d increase . Urology and Pelvic Health net sales 2018 of our consolidated net sales in 13 percent represented approximately $1245 billion Our net sales of Urology and Pelvic Health products of . Our Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies Urology and Pelvic Health was primarily driven by growth in our hemostasis franchise featuring our Resolution 360 Clip, our biliary franchise with both our SpyGlass DS Direct Visualization System and AXIOS Stent and Electrocautery Enhanced Delivery System and our infection prevention products and pathology services. increase This year over year . 2017 basis points from foreign currency fluctuations, as compared to 50 impact of positive and the 8.3 percent included operational net sales growth of increase This . 2017 , as compared to 2018 , in 8.8 percent , or $143 million d increase Our Endoscopy net sales . 2018 of our consolidated net sales in 18 percent represented approximately $1762 billion Our net sales of Endoscopy products of Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less invasive technologies. Endoscopy MedSurg of this Annual Report for additional information. Item 8. Financial Statements and Supplementary Data in consolidated financial statements to our Note A Significant Accounting Policies Refer to segment to our newly created Rhythm and Neuro segment. We have revised prior year amounts to conform to the current year presentation (as denoted with an asterisk () throughout). There was no revision to operating segments or reporting units as a result of the organizational change. MedSurg The revision reflects a reclassification of our Neuromodulation business from our . Segment Reporting FASB ASC Topic 280, Effective January 1, 2018, following organizational changes to align the structure of our business with our focus on active implantable devices, we revised our reportable segments, in accordance with of this Annual Report. Item 1 Business The following section describes an overview of our product offerings and results of operations by business unit. For additional information on our businesses and their product offerings, see Business and Market Overview 36 for further information. Liquidity and Capital Resources Refer to . $1257 billion and a working capital deficit of $146 million of Cash and cash equivalents , $7.056 billion , we had total debt of December 31, 2018 As of . 2018 in $310 million was operating activities provided by Cash 126 $ 1,752 $ Adjusted net income 0.62 861 Discrete tax Item 0.03 36 Investment impairment charges 0.12 172 Litigation related net charges (credits) 0.05 75 Restructuring and restructuring related net charges (credits) 0.01 9 Acquisition related net charges (credits) 0.00 4 Intangible asset impairment charges 0.35 492 Amortization expense Non GAAP adjustments 0.08 $ 104 $ GAAP net income (loss) Impact per Share Net Income (Loss) (in millions, except per share data) Year Ended December 31, 2017 147 $ 2,060 $ Adjusted net income ) (0.23 ) (328 Discrete tax Item 0.00 6 Investment impairment charges 0.06 79 Litigation related net charges (credits) 0.05 77 Restructuring and restructuring related net charges (credits) 0.00 5 Acquisition related net charges (credits) 0.02 31 Intangible asset impairment charges 0.37 520 Amortization expense Non GAAP adjustments 119 $ 1,671 $ GAAP net income (loss) Impact per Share Net Income (Loss) (in millions, except per share data) Year Ended December 31, 2018 for a discussion of each reconciling item Results of Operations The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to 35 for a discussion of management use of these non GAAP financial measures. Additional Information Operational net sales growth rates, which exclude the impact of foreign currency fluctuations and adjusted net income and adjusted net income per share, which exclude certain Item required by generally accepted accounting principles in the United States (U.S. GAAP), are not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to 1 1 per diluted share. $126 , or $1752 billion was 2017 Excluding these Item, adjusted net income for per diluted share. $118 (after tax), or $1647 billion included certain charges and or credits totaling 2017 Our reported results for per diluted share. $0.08 , or $104 million was 2017 in net income Our reported 1 per diluted share. $147 , or $2060 billion was 2018 Excluding these Item, adjusted net income for per diluted share. $0.28 (after tax), or $389 million included certain charges and or credits totaling 2018 Our reported results for per diluted share. $119 , or $1671 billion was 2018 in net income Our reported section for further discussion of our net sales by global business. Business and Market Overview Refer to the 1 due to the acquisitions of Symetis SA (Symetis) in the second quarter of 2017, NxThera, Inc. (NxThera) in the second quarter of 2018, Claret Medical, Inc. (Claret) in the third quarter of 2018 and Augmenix, Inc. (Augmenix) in the fourth quarter of 2018, each with no prior period related net sales. 2018 in $78 million Operational net sales included approximately basis points from foreign currency fluctuations. 60 and the positive impact of 8.0 percent , included operational growth of 8.6 percent , or $775 million of increase . This 2017 in $9.048 billion , as compared to $9.823 billion , we generated net sales of 2018 In Financial Highlights and Trends Executive Summary of this Annual Report. Item 8. Financial Statements and Supplementary Data and accompanying notes included in consolidated financial statements The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Boston Scientific Corporation and its subsidiaries. For a full understanding of our financial condition and results of operations, this discussion should be read in conjunction with our ITEM 7. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 34 of our Annual Report on Form 10 K. Item 8. Financial Statements and Supplementary Data The data above should be read in conjunction with our consolidated financial statements, including the notes thereto, included in Book value per common share is calculated using shares outstanding as of December 31, for each year, respectively shown. 4.86 $ 4.69 $ 4.94 $ 5.11 $ 6.30 $ Book value per common share 6,457 6,320 6,733 7,012 8,726 Stockholders equity 3,841 5,674 5,420 3,815 4,803 Borrowings (long term) 403 3 64 1,801 2,253 Borrowings (short term) 17,024 18,133 18,096 19,042 20,999 Total assets 760 1,041 ) (348 ) (1,832 ) (1,257 Working capital (deficit) 587 $ 319 $ 196 $ 188 $ 146 $ Cash, cash equivalents and marketable securities 2014 2015 2016 2017 2018 As of December 31, Balance Sheet Data ) (0.09 $ ) (0.18 $ 0.25 $ 0.08 $ 119 $ Assuming dilution ) (0.09 $ ) (0.18 $ 0.26 $ 0.08 $ 121 $ Basic Net income (loss) per common share ) (119 ) (239 347 104 1,671 Net income (loss) ) (509 ) (650 177 933 1,422 Income (loss) before income taxes ) (301 ) (283 447 1,285 1,506 Operating income (loss) 5,471 5,587 5,515 5,170 5,504 Total operating expenses 5,170 5,304 5,962 6,455 7,011 Gross profit 7,380 $ 7,477 $ 8,386 $ 9,048 $ 9,823 $ Net sales 2014 2015 2016 2017 2018 Year Ended December 31, Operating Data (in millions, except per share data) FIVE YEAR SELECTED FINANCIAL DATA SELECTED FINANCIAL DATA ITEM 6. 33 Note The stock price performance shown on the graph above is not indicative of future price performance. This graph shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. The graph below compares the five year total return to stockholders on our common stock with the return of the Standard & Poor (S&P) 500 Stock Index and the S&P Health Care Equipment Index. The graph assumes $100 was invested in our common stock and in each of the named indices on December 31, 2013 and that any dividends were reinvested. Stock Performance Graph 32 remaining available under the 2013 share repurchase program. $535 million of this Annual Report for additional information. As of December 31, 2018, we had approximately Item 8. Financial Statements and Supplementary Data to our consolidated financial statements contained in Note K Stockholders' Equity of our common stock. In 2014, we used $125 million of cash generated from operations to repurchase approximately 10 million shares of our common stock pursuant to our share repurchase authorizations. We made no share repurchases in 2018, 2017 or 2016. Refer to $1000 billion On January 25, 2013, our Board of Directors approved and on January 29, 2013, we announced a program authorizing the repurchase of up to Purchases of Equity Securities by the Issuer and Affiliated Purchases Please see Item 12 "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" under II of this Annual Report for information on where to find information required by Item 201(d) of Regulation S K. Securities Authorized for Issuance under Equity Compensation Plans and currently we do not intend to pay cash dividends. We may consider declaring and paying a cash dividend in the future; however, there can be no assurance that we will do so. 2016 or 2017 , 2018 We did not pay a cash dividend in Dividends holders of record of our common stock. 8,087 , there were January 31, 2019 As of Holders of Record Our common stock is traded on the New York Stock Exchange (NYSE) under the symbol BSX. Market Information ITEM 5. MARKET FOR REGISTRANT S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES I 31 Not Applicable. ITEM 4. MINE SAFETY DISCLOSURES to our consolidated financial statements included in Item 8 of this Annual Report and incorporated herein by reference. Note J Commitments and Contingencies See ITEM 3 LEGAL PROCEEDINGS Includes our principal manufacturing facilities in California, Indiana, Brazil, Switzerland and 1 in Costa Rica, and our regional headquarters located in Singapore and Voisins le Bretonneux, France. (2) Includes our principal manufacturing facilities in Minnesota, Ireland, Puerto Rico and 1 facility in Costa Rica, our manufacturing facility in Malaysia, our customer fulfillment centers in Massachusetts, the Netherlands and Japan, and our global headquarters location in Marlborough, Massachusetts. (1) 8,899,000 2,587,000 6,312,000 3,573,000 1,304,000 2,269,000 International 5,326,000 1,283,000 4,043,000 U.S. Total Leased (2) Owned (1) (in approximate square feet) December 31, 2018 , we maintained 16 principal manufacturing facilities, including seven in the U.S., 3 in Ireland, 2 in Costa Rica, 1 in Puerto Rico, 1 in Malaysia, 1 in Brazil and 1 in Switzerland, as well as various distribution and technology centers around the world. Many of these facilities produce and manufacture products for more than 1 of our divisions and include research facilities. The following is a summary of our facilities as of December 31, 2018 , our principal manufacturing and technology centers were located in Minnesota, California and Indiana within the U.S., as well as internationally in Ireland, Costa Rica, Puerto Rico, Malaysia, Brazil and Switzerland. Our products are distributed worldwide from customer fulfillment centers in Massachusetts and the Netherlands. As of December 31, 2018 Our world headquarters is located in Marlborough, Massachusetts, with regional headquarters located in Singapore and Voisins le Bretonneux, France. As of ITEM 2 PROPERTIES
